Portal de Periódicos da CAPES

Efficacy of specific immunotherapy in allergic asthma: myth or reality?

1997; Wiley; Volume: 52; Issue: 7 Linguagem: Inglês

10.1111/j.1398-9995.1997.tb01226.x

1398-9995

F. Bonifazi, Maria Beatrice Bilò,

Food Allergy and Anaphylaxis Research

AllergyVolume 52, Issue 7 p. 698-710 Free Access Efficacy of specific immunotherapy in allergic asthma: myth or reality? F. Bonifazi, Corresponding Author F. Bonifazi Allergy Respiratory Unit, Regional Hospital, Ancona, ItalyDr Floriano Bonifazi Servizio di Allergologia Respiratoria Ospedale Regionale Umberto I Largo Cappelli n. 1 Ancona 1-60100 ItalySearch for more papers by this authorM. B. Biló, M. B. Biló Allergy Respiratory Unit, Regional Hospital, Ancona, ItalySearch for more papers by this author F. Bonifazi, Corresponding Author F. Bonifazi Allergy Respiratory Unit, Regional Hospital, Ancona, ItalyDr Floriano Bonifazi Servizio di Allergologia Respiratoria Ospedale Regionale Umberto I Largo Cappelli n. 1 Ancona 1-60100 ItalySearch for more papers by this authorM. B. Biló, M. B. Biló Allergy Respiratory Unit, Regional Hospital, Ancona, ItalySearch for more papers by this author First published: 29 April 2007 https://doi.org/10.1111/j.1398-9995.1997.tb01226.xCitations: 19AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Grant IWB. Does immunotherapy have a role in the treatment of asthma? Clin Allergy 1986; 16: 7– 16. 2 Warner JO. Immunotherapy: yesterday's treatment. In: CE Reed, editor. Proceedings of XII International Congress of Allergology and Clinical Immunology. St Louis , MO : CV Mosby, 1986; 323– 6. 3 Bousquet J, Michel FB. Specific immunotherapy in asthma. In: CE Reed, editor. Proceedings of XII International Congress of Allergology and Clinical Immunology. St Louis , MO : CV Mosby, 1986; 397– 402. 4 Dreborg S, Mosbech H, Weeke B. Immunotherapy (hyposensitization) and bronchial asthma. In: AB Kay, editor. Clinical immunology and allergy. Vol 2. London : Baillière Tindall, 1988; 245– 58. 5 Ohman JL. Allergen immunotherapy in asthma: evidence for efficacy. J Allergy Clin Immunol 1989; 4: 133– 40. 6 NHLBI/WHO Workshop Report. Global Strategy for Asthma Management and Prevention. National Institutes of Health. National Heart, Lung, and Blood Institute. Publication no. 95–3659, Jan 1995. 7 Anto JM, Sunyer J, Rodriquez-Roisin R, Saurez-Cervera M, Varquez L. Toxicoepidemiological Committee. Community outbreaks of asthma associated with inhalation of soybean dust. N Engl J Med 1989; 320: 1097– 1102. 8 Platts-Mills TAE. Dust mite allergens and asthma - a worldwide problem. J Allergy Clin Immunol 1989; 83: 416– 27. 9 Zimmerman B, Chambers C, Forsyth L. Allergy in asthma. II. The highly atopic infant and chronic asthma. J Allergy Clin Immunol 1988; 81: 71– 6. 10 Sotomayor H, Badier M, Vervloet D, et al. Seasonal increase in carbachol airway responsiveness in patients allergic to grass pollen. Am Rev Respir Dis 1984; 130: 56– 65. 11 Djukanovic R, Roche WR, Wilson JH, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 434– 57. 12 Bousquet J, Chanez P, Lacoste JY, et al. Asthma: a disease remodeling the airways. Allergy 1992; 47: 3– 11. 13 Kuwano K, Bosken CH, Pare PD, et al. Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148: 1220– 5. 14 Roche WR, Williams JH, Beasley R, Holgate S. Sub-epithelial fibrosis in the bronchi of asthmatics. Lancet 1989; 1: 520– 4. 15 Brewster CEP, Howarth PH, Djukanovic R, et al. Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1990; 3: 507– 11. 16 Bousquet J, Michel FB. Specific immunotherapy in asthma: is it effective? J Allergy Clin Immunol 1994; 94: 1– 11. 17 Hill DJ, Hoshing CS, Shelton MJ, Turner MW. Growing out of asthma: clinical and immunological changes over 5 years. Lancet 1981; 2: 1359– 62. 18 Johnstone DE. Some aspects of the natural history of asthma. Ann Allergy 1982; 49: 257– 64. 19 Gorritsen J, Koeter GH, Postma DS, Schouten JP, Knol K. Prognosis of asthma from childhood to adulthood. Am Rev Respir Dis 1989; 140: 1325– 30. 20 Pearlman DS. Bronchial asthma: a perspective from childhood through adulthood-update. Pediatr Asthma Allergy Immunol 1989; 3: 191– 205. 21 Immunotherapy. EAACI Position paper. H-.I Mailing, B Weeke, editors. Allergy 1993; 48 Suppl 14. 22 Rackemann FM, Edwards MC. Asthma in children. A follow-up study of 688 patients after an interval of twenty years. N Engl J Med 1952; 246: 815– 63. 23 Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children - a 14–year study. Pediatrics 1968; 42: 793– 802. 24 Noon L, Cantar BC. Prophylactic inoculation against hay fever. Lancet 1911; 1: 1572– 3. 25 Frankland AW, Augustin R. Prophylaxis of summer hay fever and asthma: controlled trial comparing crude grass pollen extract with isolated main protein component. Lancet 1954; 1: 1055– 7. 26 Armentia-Medina A, Blanco-Quiros A, Martin-Santos JM, et al. Rush immunotherapy with a standardized Bermuda grass pollen extract. Ann Allergy 1989; 63: 127– 35. 27 Bousquet J, Maasch FIJ, Hejjaoui A, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. J Allergy Clin Immunol 1989; 84(no. 4, part 1): 546– 56. 28 Bousquet J, Hejjaoui A, Soussana M, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol 1990; 85: 490– 7. 29 Kuna P, Alam R, Kumanska B. The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled randomized study. J Allergy Clin Immunol 1989; 83: 816– 24. 30 MacAllen MK. Hyposensitisation in grass pollen hay fever. A double-blind trial of alum precipitated pollen extract and depot emulsion pollen extract compared with placebo injections. Acta Allergol 1969; 24: 421– 31. 31 Machiels IJ, Somville MA, Jaquemin MG, Sant-Remy JMR. Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergy 1991; 46: 335– 48. 32 Ortolani C, Pastorello EA, Moss RB, et al. Grass pollen immunotherapy: a single-year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984; 73: 283– 90. 33 Pastorello EA, Pravettoni V, Incorvaia C, et al. Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever. Allergy 1992; 47: 281– 90. 34 Reid M, Moss RB, Hsu YP, et al. Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol 1986; 78: 590. 35 Varney VA, Vaga M, Frew AJ, Kay B, Durham S. Usefulness of immunotherapy with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302: 265– 9. 36 Pence HL, Mitchell DQ, Grely RL, Updegraff BR, Selfridge A. Immunotherapy for mountain cedar pollinosis. A double-blind controlled study. J Allergy Clin Immunol 1976; 58(no. 1, part 1): 39– 50. 37 Leng X, Fu Y-X, Ye S-T, Duan S-Q. A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and serum-specific IgE antibody. Ann Allergy 1990; 64: 27– 31. 38 Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996; 334: 501– 6. 39 Bousquet J, Maarch H, Martinot B, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing efficacy of immunotherapy. J Allergy Clin Immunol 1988; 82: 439– 46. 40 Mailing H-J, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. VI. IgE-mediated parameters during a one-year placebo-controlled study of immunotherapy with Cladosporium. Allergy 1987; 42: 305– 14. 41 Dreborg S, Agrell B, Foucard T, Kjellman N-IM, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. Allergy 1986; 41: 131– 40. 42 Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind placebo-controlled rush immunotherapy with standardized Alternaria extract. J Allergy Clin Immunol 1990; 85: 460– 72. 43 Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994; 93: 556– 66. 44 Haugaard L, Dahl R. Immunotherapy in patients allergic to cat and dog dander. I. Clinical results. Allergy 1992; 47: 249– 54. 45 Ohman JL, Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol 1984; 74: 230– 9. 46 Sundin B, Lilja G, Graff-Lonnevig V, et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986; 77: 478– 87. 47 Taylor B, Ohman JL, Lowell FC. Immunotherapy in cat-induced asthma. Double-blind trial of bronchial responses to cat allergen and histamine. J Allergy Clin Immunol 1978; 61: 283– 7. 48 Valovirla E, Koivikko A, Vanto T, Viander M, Ingeman L. Immunotherapy in allergy to dog. Immunological and clinical findings of a double-blind study. Ann Allergy 1986; 44: 123– 31. 49 van Metre TE, Marsh DG, Adkinson NF Jr. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988; 82: 1055– 68. 50 Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985; 76: 734– 44. 51 British Thoracic Association. A trial of house dust mite extract in bronchial asthma. 1979; 73: 260– 70. 52 D'Souza ME, Pepys J, Wells ID, et al. Hyposensitization with Dermatophagoides pteronyssinus in house dust allergy: a controlled study of clinical and immunological effects. Clin Allergy 1973; 3: 177– 9. 53 Gaddie J, Skinner C, Palmer KN. Hyposensitization with house dust mite vaccine in bronchial asthma. BMJ 1976; 2: 561– 2. 54 Garcia-Ortega P, Merelo A, Marrugat J, Richart C. Decrease of skin and bronchial sensitization following short-intensive schedule immunotherapy in mite-allergic asthma. Chest 1993; 103: 183– 7. 55 Giovane AL, Bardare M, Passalacqua G, et al. A three- year double-mind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 1994; 24: 53– 9. 56 Machiels IJ, Somville MA, Lebrun PM, Lebecque SJ, Jaquemin MG, Sant-Remy JMR. Allergic bronchial asthma due to Dermatophagoides pteronyssinus can be efficiently treated by inoculation of allergen-antibody complexes. J Clin Invest 1990; 85: 1024– 35. 57 Marques RA, Avila R. Results of a clinical trial with Dermatophagoides pteronyssinus tyrosine adsorbed vaccine. Allergol Immunopathol (Madr) 1978; 6: 231– 5. 58 Newton DAG, Maberly DJ, Wilson R. House dust mite hyposensitization. Br J Dis Chest 1978; 72: 21– 8. 59 Pauli G, Bessot JC, Bigot H. Clinical and immunological evaluation of tyrosine adsorbed Dermatophagoides pteronyssinus extract; a double-blind placebo-controlled trial. J Allergy Clin Immunol 1984; 74: 524– 35. 60 van Bever HP, Stevens WJ. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mile (Dermatophagoides pteronyssinus). Eur Respir J 1992; 5: 318– 22. 61 Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978; 2: 912– 15. 62 Sly RM. Mortality from asthma. J Allergy Clin Immunol 1989; 84: 421– 34. 63 Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991; 143: 1317– 21. 64 Bousquet J, Hejjaoui A, Clauzel AM, el al. Immunotherapy with a Standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. 84. J Allergy Clin Immunol 1988; 82: 971– 7. 65 Bousquet J, Becker WM, Hejjaoui A, et al. Clinical and immunological reactivity of patients allergic to grass pollens and to multiple pollen species. II. Efficacy of a double-blind placebo-controlled specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991; 88: 43– 53. 66 Pene J, Rivier A, Lagier B, Michel FB, Bousquet J. Differences in IL-6 release by PBMC are related with heterogeneity of atopy. Immunology 1994; 81: 58– 64. 67 Parker WA, Whisman BA, Apaliski SJ, Reid MJ. The relationship between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84: 667– 77. 68 Pienkowski MM, Norman PS, Lichtenstein LM. Suppression of late-phase skin reactions by immunotherapy with ragweed extract. J Allergy Clin Immunol 1985; 76: 729– 34. 69 Fling JA, Fuff ME, Parker WA, et al. Suppression of the late cutaneous response by immunotherapy. J Allergy Clin Immunol 1989; 83: 101– 9. 70 Mailing H-J, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. Allergy 1988; 43: 60– 70. 71 Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extracts of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91: 709– 22. 72 Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cation protein in pollen-allergic patients. J Allergy Clin Immunol 1988; 82: 470– 80. 73 Murray AB, Ferguson AC, Morrison B. Non-allergic bronchial hyperreactivity in asthmatic children decreases with age and increases with mite immunotherapy. Ann Allergy 1985; 54: 541– 4. 74 Mosbech H. Who will benefit from hyposensitization? Predictive parameters in house dust mite allergic asthmatics. Allergy 1990; 45: 209. 75 Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995; 151: 969– 74. 76 Maunsell K, Wraith DG, Hughes AM. Hyposensitisation in mite asthma. Lancet 1971; 1: 967– 8. 77 Smith AP. Hyposensitisation with Dermatophagoides pteronyssinus antigen: trial in asthma induced by house dust. BMJ 1971; 4: 204– 6. 78 Brunei C, Bedard P-M, Lavoie A. Allergic rhinitis due to ragweed pollen. II. Modulation of histamine-releasing factor production by specific immunotherapy. J Allergy Clin Immunol 1992; 89: 87– 94. 79 Durham SR, Varney V, Gaga M, Frew AJ, Jacobson M, Kay AB. Immunotherapy and allergic inflammation. Clin Exp Allergy 1991; 21 Suppl 1: 206– 10. 80 Perelmutter L. IgE regulation during immunotherapy of allergic disease. Ann Allergy 1986; 57: 78– 84. 81 Prinz JC, Rieber EP, Ring J. Loss of FcR2/CD23 expression on T and B lymphocytes during rush hyposensitization. In: J Ring, B Pryzbilla, editors. New trends in allergy. III. Berlin ; Springer-Verlag, 1991; 105– 8. 82 Rak S, Håkanson L, Venge P. Immunotherapy abrogates the generation of eosinophils and neutophil chemotactic activity during pollen season. J Allergy Clin Immunol 1990; 86: 706– 13. 83 Romagnani S. Human Till and Th2: doubt no more. Immunol Today 1991; 12: 256– 7. 84 Romagnani S. Human Th1 and Th2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 1992; 98: 279– 85. 85 Kumar N, Sheikh S, Zitt M, et al. Allergen-specific interleukin (IL)-4 and interferon-gamma (IFN-gamma) production during immunotherapy (IT) in asthma. J Allergy Clin Immunol 1995; 95: 667. 86 del Prete OF, De Carli, Almerigona F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T-cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353– 60. 87 Durham SR, Schotman E, Jacobson M, et al. Grass pollen immunotherapy (IT): inhibition of allergen induced late skin responses (LPR) is associated with an increase in IL-12 messenger RNA+ cells. J Allergy Clin Immunol 1995; 95: 655. 88 Jung CM, Prinz JC, Rieber EP, Ring J. A reduction in allergen-induced FcɛR2/CD23 expression on peripheral B cell correlates with successful hyposensitization in grass pollinosis. J Allergy Clin Immunol 1995; 95: 77– 87. 89 Furin MJ, Norman PS, Creticos PS. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 1991; 88: 27– 32. 90 Rak S, Björnson A, Håkanson S, Venge P. The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J Allergy Clin Immunol 1991; 88: 878– 88. 91 Nagata M, Shibasaki M, Sakamoto Y, et al. Specific immunotherapy reduces the antigen-dependent production of eosinophil chemotactic activity from mononuclear cells in patients with atopic asthma. J Allergy Clin Immunol 1994; 94: 160– 6. 92 Forsythe P, Sim T, Reece L, et al. The effect of immunotherapy (IT) on mononuclear cell (MNC) cytokine production: heightened synthesis of IL-8 but no change in MCP-1, MlP-1–alpha or TGF-beta production. J Allergy Clin Immunol 1995; 95: 704. 93 Hsieh KH, Chou CC, Chiang BL. Immunotherapy suppresses the production of MCAF and augments the production of IL-8 in asthmatic children. J Allergy Clin Immunol 1995; 95: 669. 94 Randolph C, Franklin W. Duration of response following cessation of pollen immunotherapy. Allergy Proc 1988; 9: 567. 95 Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Allergy 1994; 73: 484– 9. 96 Mosbech H, Østerballe O. Does the effect of immunotherapy last after termination of treatment? Allergy 1988; 43: 523– 9. 97 Wihl JÅ. Long-term effect of specific immunotherapy (SIT) in tree pollen allergy. Allergy 1993; 48 Suppl 16: 73. 98 Price J, Warner J, Hey E, Turner M, Soothill J. A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspect. Clin Allergy 1984; 14: 209– 20. 99 van Bever HP, Stevens WJ. Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy. J Allergy Clin Immunol 1990; 86: 141– 6. 100 Hejjaoui A, Knani J, Dhivert H, et al. Duration of efficacy of specific immunotherapy with a standardized mite extract after its cessation. J Allergy Clin Immunol 1992; 89: 319. 101 Machiels IJ, Lebrun PM, Jaquemin MG, Sant-Remy JMR. Significant reduction of nonspecific bronchial reactivity in patients with Dermatophagoides pteronyssinus-sensitive allergic asthma under therapy with allergen-antibody complexes. Am Rev Respir Dis 1993; 147: 1407– 12. 102 van Metre TE, Adkinson NF Jr. Immunotherapy for aeroallergen disease. In: E Middleton, CE Reed, EF Ellis, et al., editors. Allergy: principles and practice. 3rd ed. St Louis , MO : CV Mosby, 1988; 1327– 43. 103 Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79: 660– 77. 104 Frankland A. Anaphylactic reactions to desensitization. BMJ 1980; 281: 1429. 105 Ancill R, Wainscott G. Anaphylactic reactions to desensitization. BMJ 1980; 281: 1429. 106 Committee on Safety of Medicines. CSM update: desensitising vaccines. BMJ 1986; 293: 948. 107 Vervloet D, Kharirallah E, Arnaud A, Charpin J. A prospective national study of the safety of immunotherapy. Clin Allergy 1980; 10: 59– 64. 108 Reid M, Lockey R, Turkeltaub P, Platts-Mills T. Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol 1993; 92: 6– 15. 109 Rachelefsky GS, Goldberg M, Katz RM, et al. Sinus disease in children with respiratory allergy. J Allergy Clin Immunol 1978; 65: 310– 14. 110 Norman PS. Peptide therapy in allergic diseases. 1995 Postgraduate Education Program, 51st Annual Meeting of AAACI, 24 Feb-1 March 1995. 111 Norman PS, Ohoman JL, Long AA, et al. Follow-up on study of the first clinical trial with T-cell defined peptides from cat allergen Fel d 1. J Allergy Clin Immunol 1995; 95: 475. 112 Sullivan TJ. Economic impact of immunotherapy in the treatment of asthma. Oral communication at AAACI, 52nd Annual Meeting, 15–20 March 1996, New Orleans, LA. Citing Literature Volume52, Issue7July 1997Pages 698-710 ReferencesRelatedInformation